News | October 13, 2014

Expert Consesus Recommends Echo to Protect Cancer Patients' Heart Health

Echocardiography is the modern method of choice for the evaluation of patients before, during, and after cancer therapy

 

October 13, 2014 – Significant numbers of patients who have been treated with chemotherapy drugs are at risk to have weakened hearts. Adult survivors of childhood cancer are 15 times as likely to have Congestive Heart Failure and 10 times as likely to have Coronary Artery Disease as their healthy siblings.  To help clinicians monitor and minimize the cardiotoxic effects of various cancer therapies, the American Society of Echocardiography (ASE) and the European Association of Cardiovascular Imaging (EACVI) have released a comprehensive new document. This paper, Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging, appears in the September issue of the Journal of the American Society of Echocardiography (JASE)

This consensus paper is the result of several years’ work to outline the specific effects of the many different cancer therapies and details the strengths and challenges of various forms of imaging in detecting and monitoring damage to the heart as early as possible.  The paper confirms that echocardiography is the modern method of choice for the evaluation of patients before, during, and after cancer therapy. The paper also strongly recommends an early baseline echocardiogram for all patients undergoing cancer therapy, and provides recommended time intervals for follow-up specific to each form of therapy used.  According to Writing Group Chair Juan Carlos Plana, M.D., FASE, former co-director of the Cardio-Oncology Clinic at the Cleveland Clinic and now a Professor of Medicine at Baylor College of Medicine, “This proactive imaging protocol is extremely helpful as it provides an accurate starting point for the patient’s normal cardiovascular health and offers the clinician early detection and warning should there be any adverse changes during the cancer treatment.”

The size of the cardio-toxicity problem is significant, as there are currently over 12 million people in the United States living with active cancer or with a history of the disease, and this number is expected to grow as screening tests become more widely available, cancer treatment improves, and the U.S. population ages.  “Once patients have survived cancer, they don't die from cancer, they die from heart disease. Cardio-oncology is about making sure that doesn't happen," said Plana.

The paper also outlines the various innovative tools that echo offers, such as three-dimensional echocardiography, myocardial deformation or “strain” imaging, contrast echocardiography, and stress echo.  Notes Dr. Plana, “While 3-D echo is the preferred echo technique for monitoring cardio-toxicity, it may not always be available.  But even when 3-D echo is not possible, 2-D echo still provides excellent information to the clinician and allows for early detection of any cardiac issues, which is the most important consideration.”  If cardiac dysfunction is detected early, cardio-protective medications can be prescribed to mitigate damage, or treatment can be modified when necessary.

In conjunction with the publication of the consensus document, Plana will conduct a live webinar, including a question and answer section, on October 29, 2014 at 5:00 p.m. ET.  The webinar will be available for free to all ASE members and open to all other clinicians for $25. 

For more information visit www.onlinejase.com.  

Related Content

Strain Imaging Improves Cardiac Surveillance of Certain Breast Cancer Patients
News | Cardio-oncology | May 03, 2017
Epsilon Imaging Inc. announced a research study using EchoInsight was presented at the American College of Cardiology (...
prostate cancer, hormone therapy, cardiac risk factors, Yale Cancer Center study, ASTRO 2016
News | Cardio-oncology | September 28, 2016
In a recent study, a Yale Cancer Center team determined that men who received hormonal therapy for prostate cancer had...
chemotherapy, radiation therapy

Epsilon’s EchoInsight software is used to help evaluate cardiotoxcity due to chemotherapy or radiation therapy.

Feature | Radiation Oncology | September 07, 2016 | By Dave Fornell
Cardio-oncology is an emerging field that combines the expertise of both cardiology and oncology to assess and treat...
Sponsored Content | Videos | Cardio-oncology | June 30, 2016
Interview with Federico Asch, M.D., FACC, FASE, associate director of the echocardiography core lab at Medstar Health
Epsilon Imaging, EchoInsight, left ventricle, LV measurement, strain imaging, ASE 2016
News | Cardiovascular Ultrasound | June 17, 2016
Epsilon Imaging Inc. announced a research study was presented at the American Society of Echocardiography (ASE) 2016...
cardio-oncology, echo strain assessment, echoinsight, epsilon

Epsilon's EchoInsight software helps analyze cardiac function by evaluating wall motion strain. 

Feature | Cardio-oncology | May 13, 2016 | Dave Fornell
Cardio-oncology is an emerging field that combines the expertise of both cardiology and oncology to assess and treat
News | Oncology Diagnostics | May 06, 2016
The Society for Cardiovascular Angiography and Interventions (SCAI) has released an expert consensus statement...
AMA, investigational CPT code, myocardial strain imaging, cardio-oncology
News | Cardiovascular Ultrasound | January 27, 2016
Effective Jan. 1, 2016, the American Medical Association (AMA) Current Procedural Terminology (CPT) Editorial Panel...
Feature | June 24, 2015
A nationwide study published in the Journal of the American College of Cardiology identified current frequent barriers...
cancer survivors, cardiovascular ultrasound, echocardiograms
News | February 17, 2015
Certain types of chemotherapy are associated with heart issues known as cancer therapeutics-related cardiac dysfunction...
Overlay Init